LSD1 Expression is Associated with Immune Exclusion and Hypoxia-Related Transcriptional Programs in Triple-Negative Breast Cancer
This study demonstrates that high LSD1 expression in triple-negative breast cancer drives a poor-prognosis phenotype characterized by hypoxia-related transcriptional programs and immune exclusion through AP-1-mediated mechanisms, suggesting LSD1 as a promising therapeutic target for immune-cold TNBC.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is not a single disease but a collection of different conditions, each with its own behavior and response to treatment. One particularly aggressive form, known as triple-negative breast cancer, lacks the specific receptors that many common therapies target, leaving doctors with fewer options. In recent years, immunotherapy has offered hope by training the body's own immune system to recognize and attack cancer cells. However, this approach often fails in triple-negative cases because the tumors create a shield, keeping immune cells at the door rather than letting them inside. This phenomenon, called immune exclusion, leaves the cancer to grow unchecked. At the same time, these tumors often struggle with a lack of oxygen, a state known as hypoxia, which forces them to rewire their internal chemistry to survive. Scientists have long suspected that the way a cell reads its genetic instructions plays a major role in these behaviors, but the specific mechanisms connecting oxygen levels, immune shielding, and genetic reading in this type of cancer have remained unclear.
A team of researchers at Singapore General Hospital and several other institutions set out to map these connections by looking at the behavior of a specific protein called LSD1. This protein acts like a molecular eraser, removing chemical tags from DNA to turn certain genes on or off. The researchers began by examining hundreds of archived tissue samples from patients with triple-negative breast cancer. They stained the tissues to see how much of this eraser protein was present in the cancer cells and then tracked how those patients fared over time. They found a stark pattern: patients whose tumors had high levels of LSD1 lived shorter lives and experienced more aggressive disease. When they looked closer at the immune landscape of these tumors, they discovered that the high-LSD1 tumors were indeed "cold," meaning they were largely empty of the immune cells needed to fight the cancer. These tumors lacked T cells, B cells, and other defenders, effectively hiding from the body's natural surveillance system.
To understand how the protein caused this, the researchers moved from looking at the tissue to looking at the molecular machinery inside the cells. They used a technique that allowed them to see exactly where the LSD1 protein was sitting on the DNA strands. They found that in the aggressive cancer cells, LSD1 was binding to thousands of specific spots on the genetic code, far more than in normal cells. At these binding sites, the researchers found a distinct pattern: the DNA sequences were shaped in a way that attracted a group of proteins known as AP-1, which are famous for driving cell growth and survival. This suggested that LSD1 was not just randomly floating around but was actively partnering with these growth proteins to rewrite the cell's instructions. Furthermore, the team noticed that the genes turned on by this partnership were often the same ones activated when a tumor is starving for oxygen, linking the protein's activity directly to the tumor's ability to survive in harsh conditions.
The study did not stop at observation; the researchers wanted to see what would happen if they stopped this protein from working. They turned to patient-derived organoids, which are tiny, three-dimensional clusters of cancer cells grown in a lab that mimic the structure of a real tumor. They treated these organoids with drugs designed to block LSD1. In these controlled experiments, the drugs successfully shrank the tumors. Crucially, when the researchers added immune cells to the mix to create a more realistic environment, the drugs continued to shrink the cancer without harming the immune cells. In fact, the treatment seemed to make the cancer cells more visible to the immune system by increasing the display of certain flags on their surface, while the immune cells themselves remained healthy and active. This indicated that the drug was targeting the cancer directly rather than just attacking the immune system.
By combining the clinical data from hundreds of patients with detailed molecular maps and laboratory experiments, the study paints a coherent picture of how this specific protein drives the disease. The high levels of LSD1 appear to act as a switch that locks the tumor into a state of rapid growth and oxygen adaptation while simultaneously suppressing the signals that would normally invite immune cells to attack. The researchers found that this protein physically interacts with growth-promoting complexes and occupies the DNA regions responsible for these aggressive traits. While the study confirms these strong associations and demonstrates the potential of blocking the protein in the lab, it notes that the direct cause-and-effect relationship in living patients requires further testing. Nevertheless, the findings offer a clear new direction: by targeting this molecular eraser, it may be possible to strip away the tumor's defenses, making it vulnerable again to the immune system and potentially improving outcomes for patients with this difficult-to-treat form of breast cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.